Raymond James & Associates Fulgent Genetics, Inc. Transaction History

Raymond James & Associates

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$47.98 - $62.75 $474,906 - $621,099	-9,898 Reduced 66.23%	5,046 $275,000
Q1 2022 May 11, 2022	BUY	$49.85 - $96.11 $223,627 - $431,149	4,486 Added 42.9%	14,944 $933,000
Q4 2021 Feb 08, 2022	BUY	$77.3 - $105.0 $240,634 - $326,865	3,113 Added 42.38%	10,458 $1.05 Million
Q3 2021 Nov 02, 2021	BUY	$74.87 - $110.87 $15,048 - $22,284	201 Added 2.81%	7,345 $661,000
Q2 2021 Aug 11, 2021	SELL	$66.8 - $100.45 $607,679 - $913,793	-9,097 Reduced 56.01%	7,144 $659,000
Q1 2021 May 14, 2021	SELL	$59.3 - $183.85 $249,534 - $773,640	-4,208 Reduced 20.58%	16,241 $1.57 Million
Q4 2020 Feb 12, 2021	BUY	$31.01 - $52.1 $161,220 - $270,867	5,199 Added 34.09%	20,449 $1.07 Million
Q3 2020 Nov 04, 2020	SELL	$15.89 - $50.51 $193,381 - $614,706	-12,170 Reduced 44.38%	15,250 $611,000
Q2 2020 Jul 28, 2020	BUY	$8.89 - $18.28 $129,660 - $266,613	14,585 Added 113.63%	27,420 $439,000
Q1 2020 Apr 21, 2020	SELL	$6.75 - $19.75 $13,972 - $40,882	-2,070 Reduced 13.89%	12,835 $138,000
Q4 2019 Feb 12, 2020	BUY	$9.29 - $15.82 $138,467 - $235,797	14,905 New	14,905 $192,000

201

16.1M

2.04M

14K

Ticker FLGT
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,265,800
Market Cap $609M
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.